Prior to 2010, docetaxel was the only treatment shown to prolong survival in metastatic castrate-resistant prostate cancer (CRPC). In the past 3 years, several therapeutic agents have demonstrated survival improvements for CRPC after the receipt of prior docetaxel, leading to multiple approvals by the US Food and Drug Administration.
INTRODUCTION
In 2004, the US Food and Drug Administration (FDA) approved docetaxel as a front-line treatment for metastatic castrate-resistant prostate cancer (mCRPC), based on its survival benefit over mitoxantrone from two randomized phase III trials [1, 2] . Since then, a number of studies with docetaxelbased combinations have been undertaken but failed to show additional benefit in overall survival (OS) [3, 4] . Hence, docetaxel was the only treatment with survival benefit in mCRPC until 2010. Consequently, patient management after docetaxel has been primarily palliative. Since 2010, there has been emergence of multiple new therapies for mCRPC. Four agents, namely sipuleucel-T, cabazitaxel, abiraterone, and enzalutamide, gained FDA approval on the merits of OS benefit. In addition, radium-223 chloride (Alpharadin) has been granted Fast Track designation by the FDA for the same. Here, we will review the results of the recent trials of the new therapies, with particular emphasis on their role in the postdocetaxel setting.
an adenosine triphosphate-dependent drug efflux pump, which is believed to be responsible for resistance to docetaxel ( Fig. 1) [6, 7] .
On the basis of its activity in solid tumors, including docetaxel-pretreated mCRPC in a phase I study [8] , the clinical efficacy and safety of cabazitaxel in postdocetaxel mCRPC were evaluated in a randomized open-label phase III trial (TROPIC, Treatment of Hormone Refractory Metastatic Prostate Cancer, ClinicalTrials.gov Identifier: NCT00417079) [9] . Seven hundred and fifty-five patients were assigned to receive cabazitaxel plus prednisone or mitoxantrone plus prednisone. Patient eligibility was not restricted to second-line chemotherapy, and 22.9% of the patients were receiving third line while 7.2% of the patients were receiving the fourth-line chemotherapy or beyond. Median OS was 15.1 months in the cabazitaxel group compared with 12.7 months in the mitoxantrone group [hazard ratio 0.70; 95% confidence interval (CI) 0.59-0.83; P < 0.0001]. Notably, subset analyses demonstrated survival benefit of cabazitaxel was more pronounced in patients who had received a longer course (!12 vs. <12 cycles) or had progressed within a shorter period after completion of docetaxel (<3 vs. !3 months), underlining its efficacy in the patients likely to be truly refractory to docetaxel. Most secondary endpoints, including progression-free survival (PFS), time to progression (TTP), and response rate (RR) for patients with radiographic measurable disease, were in favor of cabazitaxel. Prostate-specific antigen (PSA) RR was also significantly higher (39.2 vs. 17.8%, P ¼ 0.0002). However, pain RR and median time to pain were not significantly different between cabazitaxel and mitoxantrone. This may be because of the fact that mitoxantrone has active pain palliating properties [10, 11] , yet the lack of improvement of this endpoint and the potential toxicities of cabazitaxel should be taken into account during the therapeutic agent selection process for each patient.
Compared with mitoxantrone, cabazitaxel was associated with increased incidences of grade 3 or 4 neutropenia, febrile neutropenia, and diarrhea. Treatment-related mortality was considerably higher in the cabazitaxel arm (5 vs. 2.5% in the mitoxantrone arm). Seven of eighteen cabazitaxelrelated deaths were because of neutropenia-associated sepsis, but it is important to note that primary prophylaxis with growth factors was not allowed during the first cycle of treatment, and all deaths on trial occurred during the first cycle. Hence, close surveillance is mandated and prophylactic use of granulocyte colony-stimulating factors (G-CSFs) is strongly recommended.
KEY POINTS
Cabazitaxel prolongs the overall survival in docetaxelpretreated mCRPC.
Abiraterone and enzalutamide, targeting androgen synthesis and androgen-receptor signaling, respectively, represent a new generation of potent hormonal therapies that extend survival for docetaxelpretreated mCRPC.
Radium-223, an a-particle-emitting radionuclide, is being evaluated by the regulatory agencies for mCRPC with symptomatic bone metastasis, on the basis of its ability to prolong overall survival.
Sipuleucel-T, primarily indicated for asymptomatic or minimally symptomatic patients with mCRPC, should generally be reserved for the chemotherapy-naïve setting with the exception of a dramatic response to prior docetaxel treatment.
Although emergence of novel agents has markedly changed the landscape of mCRPC treatment, it has also created an urgent demand for the generation of biologic and clinical data to help form guidelines for sequencing and combinations of established and new therapeutics. With methoxyl groups in place of hydroxyl groups as shown in the shaded areas, cabazitaxel is structurally unique from docetaxel. This accounts for a larger biochemical structure and its low affinity for membrane-associated P-glycoprotein drug efflux pump, which is believed to be a mechanism for docetaxel resistance. CRPC, castrate-resistant prostate cancer.
Cabazitaxel achieved regulatory approval by the FDA in 2010 for patients with mCRPC previously treated with docetaxel. Meanwhile, questions remain over its toxicities and potential role as a first-line agent. These will be addressed in two randomized phase III trials, PROSELICA (http://clinicaltrials.gov/ct2/show/NCT01308580) and FIRSTANA (http://clinicaltrials.gov/show/ NCT01308567). The PROSELICA trial compares cabazitaxel at its currently approved dose (25 mg/m 2 ) with a lower dose (20 mg/m 2 ) to determine whether efficacy is maintained along with better tolerability, whereas the FIRSTANA trial aims to determine whether cabazitaxel is superior to docetaxel as a first-line drug in chemotherapy-naïve patients.
Mitoxantrone, one of the first cytotoxic drugs FDA-approved for mCRPC, improves the quality of life and bone pain but not OS [10, 11] . As the new therapies with survival benefit become increasingly available, use of mitoxantrone will likely decrease. Nonetheless, when access to the new agents is limited or taxanes are poorly tolerated, mitoxantrone remains a viable option.
HORMONAL THERAPY
For many years, clinical observations have suggested an important role of androgen in CRPC. For instance, retrospective studies indicated that continuation of androgen deprivation therapy (ADT) was associated with a potential survival advantage in CRPC [12] and CRPC often responds to secondary hormonal manipulation [13] . Moreover, progression of CRPC is almost invariably accompanied with rising of PSA, an androgen-responsive gene, suggesting an active androgen-signaling pathway. In the past decade, this notion has been further validated by the preclinical studies. A variety of mechanisms underlying the castration resistance have been delineated and exploited for drug development targeting androgen-signaling pathways [14, 15] .
In a castrate state, androgen is primarily synthesized by the adrenal glands and intratumorally by the cancer cells [16] [17] [18] . Cytochrome P450-17 (CYP17) represents a class of enzymes crucial to de novo androgen synthesis. The efficacy of ketoconazole, a nonselective CYP17 inhibitor, was established in a randomized phase III trial that demonstrated objective response and PSA reduction in mCRPC by combining ketoconazole with antiandrogen withdrawal. However, no OS benefit was observed. Significant toxicities, related to its nonselective inhibition on both adrenal androgen and cortisol syntheses, were also of concern [13].
Abiraterone is an oral selective inhibitor of CYP17, 10 to 30 times more potent than ketoconazole [19] . The efficacy of abiraterone in docetaxel-pretreated CRPC was evaluated in a randomized double-blind placebo-controlled trial (COU-AA-301). A total of 1195 patients were assigned to receive abiraterone plus prednisone or placebo plus prednisone. After a median follow-up of 12.8 months, an interim analysis demonstrated OS in the abiraterone group was significantly longer than in the control group (14.8 vs. 10.9 months; hazard ratio 0.65; 95% CI 0.54-0.77; P < 0.0001). Secondary endpoints, including time to PSA progression (10.2 vs. 6.6 months; P < 0.001), PFS (5.6 vs. 3.6 months; P < 0.001), and PSA reduction over 50% (29 vs. 6%, P < 0.001), were all in favor of abiraterone. Whereas mineralocorticoid excess-related adverse events, including fluid retention, hypertension, and hypokalemia, were seen more frequently with abiraterone, grade 3 or 4 events were rare [20 && ]. The potential use of abiraterone in chemotherapy-naïve patients has been assessed in a placebocontrolled phase III trial (COU-AA-302), in which 1088 patients were randomly assigned to receive abiraterone plus prednisone or placebo plus prednisone. Primary endpoints were OS and radiographic progression-free survival (rPFS). Compared to the placebo group, abiraterone led to significant improvement in rPFS (median 16.5 months vs. 8.3 months, HR 0.53; 95% CI, 0.45 to 0.62; P < 0.001) and OS (median not reached vs. 27.2 months; HR 0.75; 95% CI 0.61 to 0.93; P ¼ 0.01). All secondary endpoints including time to chemotherapy initiation, opiate use for cancer-related pain, time to PSA progression and performance status deterioration, were also met. Grade 3 or 4 mineralocorticoid-related adverse events and liver function abnormalities were more commonly seen in the abiraterone group [21 & ]. In light of this study, the FDA has now approved an expanded indication for abiraterone, in combination with prednisone, for treatment of all patients with mCRPC, including those who are chemotherapy-naïve.
Enzalutamide, formally called MDV3100, is a second-generation oral androgen receptor (AR) antagonist. It has five-fold to eight-fold higher AR-binding affinity than bicalutamide, thereby more effectively blocking AR binding by testosterone and preventing nuclear translocation, DNA binding of the ligand-AR complex, and recruitment of coactivators. Unlike bicalutamide, enzalutamide is a pure antagonist without any agonist activity [22] . In a phase I/II trial involving 140 CRPC patients who progressed on ADT or docetaxel, enzalutamide showed promising antitumor effects [23] , which led to two phase III trials in mCRPC evaluating efficacy in the postdocetaxel setting (AFFIRM, http://clinicaltrials.gov/show/NCT00974311) and the predocetaxel setting (PREVAIL, http://clinical trials.gov/show/NCT01212991).
In the AFFIRM trial, 1199 men with docetaxelpretreated mCRPC were randomly assigned to receive enzalutamide or placebo. OS, as the primary end point, was significantly longer in the treatment arm than in the placebo arm (median 18.4 vs. 13.6 months, hazard ratio 0.63; 95% CI 0.53-0.75; P < 0.001). Enzalutamide was also superior in terms of secondary endpoints, including PSA decline by at least 50% (54 vs. 2%, P < 0.001), soft-tissue RR (29 vs. 4%, P < 0.001), quality-of-life RR (43 vs. 18%, P < 0.001), time to PSA progression (8.3 vs. 3.0 months; hazard ratio 0.25; P < 0.001), rPFS (8.3 vs. 2.9 months; hazard ratio 0.40; P < 0.001), and time to the first skeletal-related event (SRE, 16.7 vs. 13.3 months; hazard ratio 0.69; P < 0.001). Side-effects were mild, including fatigue, diarrhea, musculoskeletal pain, and hot flashes, although seizure was rarely reported in the enzalutamide group (0.6%) but none in the placebo group. Notably, incidence of grade 3 or 4 events was lower in the enzalutamide group, suggesting most adverse events were disease related [24 && ]. The role of enzalutamide in the chemotherapy-naïve patients will be addressed in the PREVAIL trial that has completed accrual of 1680 patients worldwide. Primary endpoints include OS and rPFS.
Orteronel is an oral nonsteroidal CYP17 inhibitor. Because of its higher selectivity for 17,20-lyase over 17-hydroxylase, it is less likely to cause mineralocorticoid excess, hence requires no concomitant use of steroid when lower doses are used [25] . A phase I/II study of orteronel in chemotherapy-naïve CRPC patients showed encouraging results based on PSA reduction and Response Evaluation Criteria in Solid Tumors (RECIST) [26] . Of note, similar efficacy was seen in groups not receiving concomitant steroid, and mineralocorticoid-related side-effects were uncommon. The use of orteronel in chemotherapy-naïve and postdocetaxel CRPC is being evaluated in two randomized, placebo-controlled, phase III trials (http://clinicaltrials.gov/show/ NCT01193244; http://clinicaltrials.gov/show/ NCT01193257); however, both trials use higher doses of orteronel accompanied with steroids.
Resistance to abiraterone or enzalutamide has been observed in preclinical models and tumorderived xenografts [27] [28] [29] . Unfortunately, no biomarker is available to predict response or resistance to either agent. Underlying biologic mechanisms of resistance in humans will need to be determined from tissue-based and marker-based trials. Only then will optimal sequencing and combination of these agents be understood.
BONE-TARGETED THERAPY
Symptomatic bone metastases are a primary cause of morbidity and decreased quality of life in patients with mCRPC. Bone-targeted therapy, including bisphosphonates and denosumab, is now the standard of care to reduce the risk of SREs [30, 31] . Boneseeking radiopharmaceuticals have been used primarily for refractory bone pain despite systemic therapy and focally directed external beam radiation therapy. Samarium-153 and Strontium-89 are b-particle-emitting radionuclides approved by the FDA for pain palliation in mCRPC [32, 33] . However, their use has been limited by b-emission-induced myelosuppression. Moreover, none of the b-emitters (e.g. strontium, samarium, and rhenium) have been shown to prolong survival.
Radium-223 (Alpharadin) is a first-in-class a-particle-emitting radionuclide. Grouped in the same column as calcium on the periodic element table, radium shares similar chemical properties with calcium, thus serves as a calcium mimic by being incorporated in osteoblastic bone lesions, for instance metastatic sites from prostate cancer. Compared with b-emitters, it delivers higher energy with a shorter range (less than 100 mm) thereby sparing surrounding bone marrow and reducing myelotoxicity. A randomized, placebo-controlled, phase III trial (ALSYMPCA, ALpharadin in SYMptomatic Prostate CAncer, http://clinicaltrials.gov/ct2/show/ NCT00699751) evaluated radium-223 in 921 patients with symptomatic bone mCRPC either after docetaxel, or unfit for or refusing docetaxel. Results of an interim analysis showed radium-223 significantly improved OS compared with placebo (median 14.0 vs. 11.2 months; hazard ratio 0.695; 95% CI 0.552-0.875; two-sided P ¼ 0.00185), and extended time to first SREs (median 13.6 vs. 8.4 months; hazard ratio 0.610; 95% CI 0.461-0.807;
]. An updated analysis presented at the ASCO 2012 further extended the median survival benefit to 3.6 months (14.9 vs. 11.3 months; hazard ratio 0.695; 95% CI 0.581-0.832; P ¼ 0.00007), as well as the median time to first SREs (15.6 vs. 9.8 months; hazard ratio 0.658; 95% CI 0.522-0.830; P ¼ 0.00037). Of note, significant OS benefit was demonstrated in both the chemotherapy-naïve (median 16.1 vs. 11.5 months, hazard ratio 0.745, 95% CI 0.562-0.987; P ¼ 0.03932) and the postdocetaxel subgroup (median 14.4 vs. 11.3 months; hazard ratio 0.710; 95% CI 0.565-0.891; P ¼ 0.00307). Safety profile of radium-223 remained favorable with a low risk of myelosuppression and diarrhea [35 & ]. The FDA will be evaluating these data in the near future.
IMMUNOTHERAPY
The role of immune-based therapy has been actively investigated in prostate cancer because of its long natural course and immunogenicity of antigens specific for prostate, for example, PSA and prostatic acid phosphatase (PAP). Sipuleucel-T is an autologous dendritic cell product manufactured via activation in vitro with a recombinant fusion protein composed of granulocyte macrophage colonystimulating factor (GM-CSF) and PAP [36] .
The impact of sipuleucel-T on survival was confirmed in a double-blind, placebo-controlled, phase III trial (IMPACT, IMmunotherapy Prostate Adeno-Carcinoma Treatment), in which 512 patients with asymptomatic or minimally symptomatic mCRPC were randomized to receive either sipuleucel-T or placebo. The median OS was 25.8 months in the treatment group vs. 21.7 months in the placebo group (hazard ratio 0.78; 95% CI 0.61-0.98; P ¼ 0.03). Notably, in a subset analysis, benefit from sipuleucel-T treatment was seen in both those who did (only 14.4% of overall population) and those who did not receive prior docetaxel chemotherapy [37] . The NCCN prostate cancer panel listed sipuleucel-T as a category 2A option 'after failure of, or treatment with, chemotherapy in asymptomatic or minimally symptomatic patients with good performance status' [38] .
Ipilimumab, a monoclonal antibody against a cytotoxic T-lymphocyte antigen, already FDA approved for metastatic melanoma, is being evaluated in a randomized, double-blind, placebo-controlled, phase III trial in mCRPC patients pretreated with docetaxel (http://clinicaltrials.gov/show/ NCT00861614).
NOVEL AGENTS IN PIPELINE
A number of unique novel agents are currently in phase III trials for postdocetaxel mCRPC. Among them are cabozantinib (XL-184) and custirsen (OGX-011).
Cabozantinib is a tyrosine kinase inhibitor of c-MET, VEGFR2, and multiple other kinases. Results from a randomized, discontinuation phase II trial presented at the ASCO 2011 showed impressive RRs in bone scan resolution (86%), pain relief (64%), and overall disease control (71%), which led to discontinuation of randomization and expansion of the treatment cohort [39] . Data from the nonrandomized expansion cohort in 93 docetaxel-pretreated patients was reported at ASCO 2012 and showed again high rates of bone scan response (70%), durable pain reduction (49% !6 weeks), along with declines in bone turnover markers (74, 67, and 47% in C-telopeptide, N-telopeptide, and bone alkaline phosphatase, respectively) and circulating tumor cells [40] . Treatment-related toxicity can be significant with fatigue, anorexia, weight loss, and gastrointestinal disturbance, and discontinuation or dose reduction was required for many patients when 100 mg each day was used. Two randomized phase III trials, evaluating the efficacy of cabozantinib 60 mg each day for OS (COMET-1, http://clinical trials.gov/ct2/show/NCT01605227) and pain response (COMET-2, http://clinicaltrials.gov/ct2/ show/NCT01522443) after treatment with docetaxel, are ongoing.
Custirsen is an antisense inhibitor of clusterin, a chaperone protein whose increased expression promotes the survival of cancer cells. It has been shown that custirsen, combined with docetaxel as a first-line treatment, prolonged OS in mCRPC compared with docetaxel alone (median 23.8 vs. 16.9 months) [41] . In patients with progressive CRPC after first-line docetaxel, combination of docetaxel and custirsen showed an encouraging RR in pain relief (77%), with interesting correlations between serum clusterin level and survival [42] . A randomized, open-label, phase III trial (SYNERGY) comparing docetaxel to docetaxel plus custirsen in chemotherapy-naïve patients is now fully accrued with results pending (http://clinicaltrials.gov/show/NCT01188187). A phase III trial (AFFINITY) has been recently initiated to compare cabazitaxel plus prednisone in combination with custirsen to cabazitaxel plus prednisone for patients who have received prior docetaxel (http://clinicaltrials.gov/ct2/show/ NCT01578655).
RECOMMENDATIONS
It should be noted that prostate cancer, even at a castrate-resistant stage, is a group of heterogeneous diseases. Thus, management of patients after docetaxel needs to be individualized. Nevertheless, because of the lack of predictive biomarkers and comparative clinical trial data, therapeutic agent selection is generally based upon clinical parameters, for example, age, performance status, symptoms, elapsed time from last treatment, pace of disease, location of metastases, and, often, individual preferences.
We concur with the NCCN recommendations that sipuleucel-T, although appropriate for asymptomatic or minimally symptomatic patients, should be avoided for those with rapidly progressive disease, visceral metastasis, or life expectancy less than 6 months. Generally, it should be reserved for the chemotherapy-naïve patient; however, in unique situations where patients gain an impressive response to chemotherapy, deserving of a prolonged chemotherapy break, sipuleucel-T can be considered.
Cabazitaxel, abiraterone, and enzalutamide are all reasonable options for patients with symptomatic progressive mCRPC in the postdocetaxel treatment paradigm. Abiraterone or enzalutamide may be reasonable agents immediately after docetaxel for the practical reason that the side-effect profiles are favorable, allowing patients to recover from chemotherapy toxicities. In addition, patients with limited performance status or intolerance to cabazitaxel will likely tolerate either abiraterone or enzalutamide. As mentioned above, while enzalutamide is currently being evaluated in chemotherapy-naïve patients, indication for abiraterone has already been expanded to chemotherapy naïve patients with mCRPC. Therefore, abiraterone, and possibly enzalutamide, will serve as a continuum of ADT in the pre-docetaxel setting, and consequently, chemotherapy such as docetaxel and cabazitaxel will be further deferred (Fig. 2) .
Radium-223, if approved by the FDA, will likely be an excellent selection for patients with symptomatic bone metastasis either prior to or after docetaxel. As a bone-seeking radionuclide, its survival benefit may be partly derived from targeting tumor microenvironment, which makes combinatorial use with other nontoxic agents an attractive option for future trials.
CONCLUSION
The emergence of new effective therapies has ushered in an exciting new era for prostate cancer therapy in the postdocetaxel setting. Patients have more options to help prolong survival. Yet, clinicians are faced with an unprecedented challenge of maximizing benefit with the enriched armamentaria without any data to drive these decisions. Biomarker studies with tissue acquisition and molecular characterization of circulating tumor cells are logical research tools to aid in the understanding of drug sensitivity and resistance. Only with further such work can safe, intelligent sequencing, and combinations be developed and introduced to earlier prostate cancer disease states with the hope of even greater patient benefit. As a result, it cannot be overemphasized that participation in clinical trials is strongly encouraged to continue to facilitate more groundbreaking advances.
